Quantum convoy covers 1,000 miles for cancer

Pharmaceutical specials manufacturer raises £5,000 for charity

Ten amateur cyclists from pharmaceutical manufacturer Quantum Pharmaceutical have completed a 1,000-mile charity bike ride to raise £5,000 for Marie Curie Cancer Care.

The team signed up for the challenge after their colleague Tony Gallagher died of cancer in 2008.

Gallagher’s son, Scott, led the cycle convoy, which rode off from Land’s End in Cornwall and cycled up to 90 miles a day to cross the finishing line at John O’Groats in Caithness, Scotland a fortnight later.

‘It was a testing couple of weeks,’ said Quantum Pharmaceutical’s managing director Andy Scaife.

‘We remember Tony so fondly, and cycling a thousand miles will be nothing compared with the challenge he faced in fighting cancer. We just hope the money we raise will help other cancer sufferers as they battle with the disease.’

Quantum Pharmaceutical, based in Burnopfield, Co Durham, UK, is a pharmaceutical specials manufacturer licensed by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to supply pharmacies, chemists, dispensing doctors and hospitals with bespoke medicines.

You may also like

Regulatory

Penn Pharma recalls batches of seizure drug

Following incorrect placement of screw caps on some units of Midazolam buccal liquid, which could affect drug concentration
Containment

Quantum Pharmaceutical opens aseptic manufacturing facility

Incorporates aseptic compounding and manufacturing services, including gassing isolators
Manufacturing

Quantum Pharmaceutical moves into new HQ

Opens up potential for further expansion of the UK specials manufacturer
Pharma 5.0

Mursla Bio announces partnership with a "leading global pharma company"

Partnering with a company recognised for its "expertise in precision medicine and biomarker-guided drug development", Mursla Bio will use its AI Precision Medicine Platform to inform drug development and patient stratification in metabolic liver disease
Regulatory

BetaGlue Therapeutics gains MHRA approval for pancreatic cancer trial

YntraDose, the innovative radiotherapy treatment for unresectable locally advanced pancreatic cancer, has been granted an early feasibility clinical investigation and will assess safety and performance in patients
Research & Development

Scottish immunology CRO RoukenBio celebrates 10 years of growth

Formerly known as Antibody Analytics, the contract research organisation has grown from three employees to over 100 and enjoyed successes such as the launch of its first proprietary technology, IndEx-2 and multi-million pound investments
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

The cross-pollination effect: how shared learnings bear fruit for drug sponsors

This article explores how contract development and manufacturing organisations leverage the cross-pollination of knowledge to help drug sponsors overcome critical challenges in pharmaceutical development
Subscribe now